Reports Q3 revenue $84.51M, consensus $65.77M. “Novavax (NVAX) continues to focus on our corporate growth strategy of driving value from additional business development activities and organic R&D using our proven technology platform,” said John Jacobs, President and Chief Executive Officer, Novavax. “In addition to progress on our other value drivers, this past quarter, we made significant progress defining our R&D strategy as we look to expand beyond COVID-19 and influenza. We intend to develop our early-stage pipeline with a disciplined approach, as we focus on areas where our technology can have a positive impact on public health and generate value.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Options Volatility and Implied Earnings Moves Today, November 12, 2024
- Unusually active option classes on open November 11th
- Novavax: FDA removes clinical hold on Covid-19/flu combo trial
- Options Volatility and Implied Earnings Moves This Week, November 11 – November 15, 2024
- Novavax Settles Vaccine Supply Agreement Dispute